THURSDAY, Oct. 13, 2022 (HealthDay News) -- People with attention-deficit/hyperactivity disorder (ADHD) or narcolepsy may rely on the drug Adderall, but it is in short supply, the U.S. Food and Drug Administration announced Wednesday.
The Adderall and Adderall IR shortage is due to intermittent manufacturing delays at Teva, one of the companies that produces the medication.
While other companies continue to produce these amphetamine mixed salts, they don't make enough to meet U.S. demand.
Adderall is FDA-approved for ADHD and narcolepsy, a sleep disorder.
Until supply is restored, alternatives include the extended-release version of amphetamine mixed salts, the FDA said.
The FDA has posted information online on current manufacturers and available product strengths. It is monitoring the shortage and helping manufacturers get what they need to resolve it. The agency said it would continue to provide updates.
Patients should work with their doctors to determine their best treatment option, according to a news release from the FDA's Center for Drug Evaluation and Research.
More information
The U.S. Centers for Disease Control and Prevention has more on ADHD.
SOURCE: Center for Drug Evaluation and Research, news release, Oct. 12, 2022
